Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $126.02 USD
Change Today -1.41 / -1.11%
Volume 184.2K
ALNY On Other Exchanges
As of 11:37 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Akshay K. Vaishnaw M.D., Ph.D.

Chief Medical Officer and Executive Vice President of Research and Development, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 17 board members in 2 different organizations across 3 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Akshay K. Vaishnaw, MD, Ph.D., has been Chief Medical Officer of Alnylam Pharmaceuticals, Inc. since June 13, 2011 and has been its Executive Vice President of Research and Development since December 2014. Dr. Vaishnaw served as Executive Vice President of Alnylam Pharmaceuticals, Inc. June 2012 to December 2014. He served as Senior Vice President of Clinical Research at Alnylam Pharmaceuticals, Inc. from December 2008 to June 13, 2011 and served as its Senior Vice ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*



Harvard Business School
University Of London
University Of Wales College Of Medicine
University of Wales School of Medicine

Other Affiliations*

Annual Compensation*

Total Annual Compensation$463,500

Stock Options*

All Other Compensation$7,596
Exercised Options64,645
Exercised Options Value$4,263,810
Exercisable Options212,059
Unexercisable Options71,875
Total Value of Options$4,263,810
Total Number of Options370,245

Total Compensation*

Total Annual Cash Compensation$720,096
Total Short Term Compensation$463,500
Other Long Term Compensation$7,596
Total Calculated Compensation$720,096
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $126.02 USD -1.41


Stanley T. Crooke M.D., Ph.D.Founder, Executive Chairman, Chief Executive Officer, President, Chairman of Science/Medical Committee and Member of Agenda Committee
Isis Pharmaceuticals, Inc.
Edward M. Kaye M.D., Ph.D.Interim Chief Executive Officer, Chief Medical Officer and Senior Vice President
Sarepta Therapeutics, Inc.
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at